Background:With the rapid evolution in treatment strategies and the increasing range of available therapeutics for rheumatoid arthritis (RA), keeping pace with advances can be a challenge for busy physicians.Objectives:We assessed whether online CME can improve rheumatologists’ knowledge of RA management focusing on the assessment and monitoring of RA, the selection of appropriate treatments and the clinical efficacy and safety data for JAK inhibitors.Methods:Rheumatologists participated in a text-based activity featuring two patient cases with questions that “tested” knowledge and discussion of the main “teaching” points. Educational effect was assessed using a repeated-pair design, pre-/post-assessment. A Chi-square test of independence determined if a statistically significant improvement (5% significance level,P<.05) existed in the number of correct responses between the pretest and posttest scores. Cramer’s V estimated the effect size of the education. The activity launched on 15 December 2018 with data collection through 27 February 2019.Results:•Significant improvement in average percentage of correct responses, rising from 47% at baseline to 92% post-activity (P<.001) and extensive educational impact (Cramer’s V=0.496)•Significant increase in percentage of rheumatologists (n=111) answering all 3 questions correctly (9% at baseline rising to 78% post assessment)•Significant improvements in knowledge of EULAR/ACR assessment criteria (86% improvement,P<.001), EULAR treatment recommendations for a patient failing on MTX and a TNF inhibitor (100% improvement,P<.001), and the VTE risk associated with having RA or receiving RA treatments (108% improvement,P<.001)•46% of rheumatologists reported greater confidence in their ability to appropriately incorporate JAK inhibitors into the treatment of patients with RA (average confidence shift 20%)Conclusion:Overall, this learning activity was highly successful in improving rheumatologists’knowledge and confidence in managing patients with RA, particularly with regard to the appropriate use of JAK inhibitors in patients for whom such treatment is suitable. The extensive impact of this interactive ‘test then teach’ activity is likely to directly translate into patient benefit. Further education on this topic would be useful to enhance and reinforce this knowledge and to support physician confidence in the use of JAK inhibitors in clinical practice.References:[1]https://www.medscape.org/viewarticle/906202Disclosure of Interests:Elaine Bell: None declared, Anne Sendaydiego: None declared, Peter C. Taylor Grant/research support from: Celgene, Eli Lilly and Company, Galapagos, and Gilead, Consultant of: AbbVie, Biogen, Eli Lilly and Company, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Roche, and UCB